Deep Lens, Inc., a Columbus, OH-based digital pathology startup, exited stealth mode with $3.2m in seed financing.
The round was led by Sierra Ventures, with participation from Rev1 Ventures and Tamarind Hill Fund. In conjunction with the financing, Mark Shary, managing member of Tamarind Hill, and Dr. Jeff Elton, CEO of Concerto Health AI, will join Deep Lens’ board of directors.
The company intends to use the funds for technology development and deployment.
Led by Dave Billiter, co-founder and CEO, Deep Lens is a digital pathology startup combining artificial intelligence (AI) and advanced, cloud-based, pathology workflows to improve efficiency and enable patient access to cancer clinical trials.
VIPER (Virtual Imaging for Pathology Education and Research), which is now available as a public beta, will soon include AI-powered image detection, workflow support, telepathology, cloud storage, and built-in APIs for integration by hardware and software vendors and biopharma companies.